Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Neoplasms 2Acromegaly 2Serotonin Syndrome 1Pituitary Neoplasms 1Pancreatitis 1Pancreatic Intraductal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Fistula 1Duodenal Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Adenoma 1

Interventions

arginyllysine 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoid Tumor × Octreotide × Clear all
NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡